In intestinal epithelial cells, inactivation of APC, a key regulator of the Wnt pathway, activates beta-catenin to initiate tumorigenesis. However, other alterations may be involved in intestinal tumorigenesis. Here we found that RUNX3, a gastric tumor suppressor, forms a ternary complex with beta-catenin/TCF4 and attenuates Wnt signaling activity. A significant fraction of human sporadic colorectal adenomas and Runx3(+/-) mouse intestinal adenomas showed inactivation of RUNX3 without apparent beta-catenin accumulation, indicating that RUNX3 inactivation independently induces intestinal adenomas. In human colon cancers, RUNX3 is frequently inactivated with concomitant beta-catenin accumulation, suggesting that adenomas induced by inactivation of RUNX3 may progress to malignancy. Taken together, these data demonstrate that RUNX3 functions as a tumor suppressor by attenuating Wnt signaling.
Due to a mistake made during manuscript preparation, the Supplemental Data for this article listed incorrect sequences for the primer sets for methylation-specific PCR (MSP). The correct sequences are given below. These corrections do not affect the findings or conclusions of the study.Primer sets used for detection of methylated DNA were 5 0 -ataaagagaaattaggcgc-3 0 and 5 0 -ataaccctcgaaaaacgcg-3 0 (M3), 5 0 -gatgttt gtttaggtcgtagcggtc-3 0 and 5 0 -ccaaactcgaaattcgccgta-3 0 (M2), and 5 0 -tgcgattggttgcgtttcgc-3 0 and 5 0 -cgaaaatacgcataccgcg-3 0 (M1). Primer sets used for detection of unmethylated DNA were 5 0 -ataaagagaaattaggtgt-3 0 and 5 0 -ataaccctcaaaaaacaca-3 0 (M3), 5 0 -tgtttg tttaggttgtagtggttgt-3 0 and 5 0 -cccccaaactcaaaattcaccata-3 0 (M2), and 5 0 -tgtgattggttgtgttttgt-3 0 and 5 0 -caaaaatacacataccaca-3 0 (M1).
The RUNX1/AML1 gene encodes a transcription factor essential for the generation of hematopoietic stem cells and is frequently targeted in human leukemia. In human RUNX1-related leukemias, the RAS pathway is often concurrently mutated, but the mechanism of the synergism remains elusive. Here, we found that inactivation of Runx1 in mouse bone marrow cells results in an increase in the stem/progenitor cell fraction due to suppression of apoptosis and elevated expression of the polycomb gene Bmi-1, which is important for stem cell self-renewal. Introduction of oncogenic N-RAS into wild-type cells, in contrast, reduced the stem/ progenitor cell fraction because of senescence, apoptosis, and differentiation. Such detrimental events presumably occurred because of the cellular fail-safe program, although hyperproliferation was initially induced by an oncogenic stimulus. Runx1 insufficiency appears to impair such a failsafe mechanism, particularly in the stem/progenitor cells, thereby supporting the clonal maintenance of leukemiainitiating cells expressing an activated oncogene. STEM CELLS
Chronic granulomatous disease (CGD) is an inherited disorder of host defense against microbial infections caused by defective activity of the phagocyte NADPH oxidase. Based on an increase of neutrophil superoxide-generating ability in response to interferon ␥ (IFN-␥) in a single patient with CGD, multicentered group studies demonstrated a beneficial effect of prophylactic IFN-␥. However, no apparent increase of the phagocyte superoxide generation was found in patients enrolled in these studies. The present report offers an additional kindred in whom an IFN-␥-dependent increase in neutrophil superoxide production was observed in 3 affected patients. The defect in the CYBB gene for gp91-phox was identified as an otherwise silent mutation adjacent to the third intron of the CYBB gene that alters messenger RNA splicing. By molecular analysis, significant differences were found in the splicing pattern of CYBB gene transcripts in patient neutrophils between 1 and 25 days after administration of IFN-␥. IntroductionChronic granulomatous disease (CGD) is an inherited disorder of host defense against bacterial and fungal infections; affected patients suffer from severe recurrent and intractable infections beginning in early childhood. 1 Phagocytes from patients with CGD show impaired microbicidal activity due to defects in the superoxidegenerating phagocyte oxidase. 1 It is known that the mutations responsible for CGD reside within the genes for 4 essential components of the oxidase designated as gp91-phox (phagocyte oxidase), p22-phox, p47-phox and p67-phox. 2,3 The gp91-phox forms membrane cytochrome b 558 together with p22-phox and plays an essential role in the transfer of electrons following assembly of the active oxidase with the cytoplasmic p47-and p67-phox components. Patients with CGD with gp91-phox defects account for the majority of cases, and in most instances the cytochrome is reduced or absent in phagocytes and B lymphocytes. The CYBB gene that encodes gp91-phox is localized to Xp21.1 and encompasses 13 exons spanning approximately 30 kilobases (kb). Mutations in the CYBB gene are heterogenous, and include missense, nonsense, deletion, insertion, and splicing defects. 1,4,5 Various cytokines have been studied for enhancement of the neutrophil superoxide generation, showing that IFN-␥ may be an effective agent. 6,7 Ezekowitz and coworkers first demonstrated that phagocytes of a patient with X-linked CGD were responsive to interferon-␥ (IFN-␥), which almost completely corrected the oxidase defect in vitro and in vivo. 8,9 These findings motivated multicenter groups to perform double-blinded clinical studies of IFN-␥ as a prophylactic agent in CGD, which demonstrated its clinical benefit in the majority of patients with CGD. 10,11 In these group studies, however, no apparent increases in phagocyte superoxide generation were observed. The patient studied by Ezekowitz and colleagues, therefore, has been considered to be an exceptional case. Recently, the mutation in this patient has been identified as a single b...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.